NO742216L - - Google Patents

Info

Publication number: NO742216L
Authority: NO; Norway
Prior art keywords: factor; fibrinogen; cross; gel; solution
Prior art date: 1973-06-19

Application number

NO742216A

Other languages

English (en)

Norwegian (no)

Inventor

L-O Andersson

H G Borg

E C Ehrenberg

N Forsman

G Hanshoff

G Lindroos

M Miller-Andersson

Original Assignee

Kabi Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1973-06-19

Filing date

1974-06-18

Publication date

1975-01-13

1974-06-18 Application filed by Kabi Ab filed Critical Kabi Ab

1975-01-13 Publication of NO742216L publication Critical patent/NO742216L/no

Links

108010049003 Fibrinogen Proteins 0.000 claims description 73
102000008946 Fibrinogen Human genes 0.000 claims description 73
102100026735 Coagulation factor VIII Human genes 0.000 claims description 70
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 70
229940012952 fibrinogen Drugs 0.000 claims description 70
239000000243 solution Substances 0.000 claims description 69
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 48
238000000034 method Methods 0.000 claims description 45
108010076282 Factor IX Proteins 0.000 claims description 41
210000002381 plasma Anatomy 0.000 claims description 41
102100022641 Coagulation factor IX Human genes 0.000 claims description 37
229960004222 factor ix Drugs 0.000 claims description 35
239000000872 buffer Substances 0.000 claims description 32
229920000936 Agarose Polymers 0.000 claims description 31
229920002307 Dextran Polymers 0.000 claims description 28
229960002086 dextran Drugs 0.000 claims description 28
239000011780 sodium chloride Substances 0.000 claims description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
239000010836 blood and blood product Substances 0.000 claims description 21
229960000633 dextran sulfate Drugs 0.000 claims description 21
229940125691 blood product Drugs 0.000 claims description 20
238000010828 elution Methods 0.000 claims description 20
239000003463 adsorbent Substances 0.000 claims description 17
239000011159 matrix material Substances 0.000 claims description 16
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 15
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 15
239000003114 blood coagulation factor Substances 0.000 claims description 15
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 13
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
229920000669 heparin Polymers 0.000 claims description 13
229960002897 heparin Drugs 0.000 claims description 13
239000001509 sodium citrate Substances 0.000 claims description 13
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 13
239000002156 adsorbate Substances 0.000 claims description 12
241001465754 Metazoa Species 0.000 claims description 10
210000004369 blood Anatomy 0.000 claims description 10
239000008280 blood Substances 0.000 claims description 10
108010054218 Factor VIII Proteins 0.000 claims description 9
102000001690 Factor VIII Human genes 0.000 claims description 9
229940019700 blood coagulation factors Drugs 0.000 claims description 8
VAANUEHPYNAMQR-UHFFFAOYSA-N 5-amino-2-(4-aminophenyl)cyclohexa-2,4-diene-1,1-disulfonic acid Chemical compound OS(=O)(=O)C1(S(O)(=O)=O)CC(N)=CC=C1C1=CC=C(N)C=C1 VAANUEHPYNAMQR-UHFFFAOYSA-N 0.000 claims description 7
238000000502 dialysis Methods 0.000 claims description 6
229960000301 factor viii Drugs 0.000 claims description 6
238000000926 separation method Methods 0.000 claims description 6
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 5
229920001287 Chondroitin sulfate Polymers 0.000 claims description 5
102000013831 Coagulation factor IX Human genes 0.000 claims description 5
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 5
229940059329 chondroitin sulfate Drugs 0.000 claims description 5
229940105774 coagulation factor ix Drugs 0.000 claims description 5
238000004108 freeze drying Methods 0.000 claims description 5
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 5
WPANETAWYGDRLL-UHFFFAOYSA-N 4-aminobenzenecarboximidamide Chemical group NC(=N)C1=CC=C(N)C=C1 WPANETAWYGDRLL-UHFFFAOYSA-N 0.000 claims description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
238000001556 precipitation Methods 0.000 claims description 3
230000008859 change Effects 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
239000004520 water soluble gel Substances 0.000 claims description 2
229910017053 inorganic salt Inorganic materials 0.000 claims 2
108090000056 Complement factor B Proteins 0.000 claims 1
102000003712 Complement factor B Human genes 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
238000004090 dissolution Methods 0.000 claims 1
150000002500 ions Chemical class 0.000 claims 1
239000012460 protein solution Substances 0.000 claims 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
239000000499 gel Substances 0.000 description 123
229920002684 Sepharose Polymers 0.000 description 45
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 28
239000012141 concentrate Substances 0.000 description 26
239000007858 starting material Substances 0.000 description 26
238000002360 preparation method Methods 0.000 description 23
239000000203 mixture Substances 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 22
108090000623 proteins and genes Proteins 0.000 description 22
238000001179 sorption measurement Methods 0.000 description 22
230000000694 effects Effects 0.000 description 21
238000003756 stirring Methods 0.000 description 16
229920005654 Sephadex Polymers 0.000 description 10
238000005194 fractionation Methods 0.000 description 10
239000012507 Sephadex™ Substances 0.000 description 9
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 9
239000000463 material Substances 0.000 description 8
208000032843 Hemorrhage Diseases 0.000 description 7
239000011149 active material Substances 0.000 description 7
230000023555 blood coagulation Effects 0.000 description 7
238000002955 isolation Methods 0.000 description 7
239000000047 product Substances 0.000 description 7
238000000746 purification Methods 0.000 description 7
108010048049 Factor IXa Proteins 0.000 description 6
239000007979 citrate buffer Substances 0.000 description 6
238000003795 desorption Methods 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
229910000033 sodium borohydride Inorganic materials 0.000 description 6
239000012279 sodium borohydride Substances 0.000 description 6
239000004023 fresh frozen plasma Substances 0.000 description 5
238000002523 gelfiltration Methods 0.000 description 5
230000008569 process Effects 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
208000009292 Hemophilia A Diseases 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
239000011324 bead Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
208000034158 bleeding Diseases 0.000 description 4
230000000740 bleeding effect Effects 0.000 description 4
239000012847 fine chemical Substances 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
229910021653 sulphate ion Inorganic materials 0.000 description 4
JCUYNPHEESTECG-UHFFFAOYSA-N 3-amino-6-(4-aminophenyl)benzene-1,2-disulfonic acid Chemical group C1=CC(N)=CC=C1C1=CC=C(N)C(S(O)(=O)=O)=C1S(O)(=O)=O JCUYNPHEESTECG-UHFFFAOYSA-N 0.000 description 3
208000031220 Hemophilia Diseases 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
229940105778 coagulation factor viii Drugs 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
208000009429 hemophilia B Diseases 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241001146702 Candidatus Entotheonella factor Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
238000000760 immunoelectrophoresis Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
ZBZGGZGVFCIXDE-UHFFFAOYSA-N 5-amino-2-(4-aminophenyl)benzenesulfonic acid Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1S(O)(=O)=O ZBZGGZGVFCIXDE-UHFFFAOYSA-N 0.000 description 1
229910018626 Al(OH) Inorganic materials 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
229920002567 Chondroitin Polymers 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
108010035369 Cohn fraction I Proteins 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
201000003542 Factor VIII deficiency Diseases 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
108010074864 Factor XI Proteins 0.000 description 1
206010018852 Haematoma Diseases 0.000 description 1
206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
206010060820 Joint injury Diseases 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
101000884740 Tachypleus tridentatus Clotting factor B Proteins 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000002085 hemarthrosis Diseases 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
208000018937 joint inflammation Diseases 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical group 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
239000000052 vinegar Substances 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)

NO742216A 1973-06-19 1974-06-18 NO742216L (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US371491A US3920625A (en)	1973-06-19	1973-06-19	Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates

Publications (1)

Publication Number	Publication Date
NO742216L true NO742216L (zh)	1975-01-13

Family

ID=23464186

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO742216A NO742216L (zh)	1973-06-19	1974-06-18

Country Status (13)

Country	Link
US (1)	US3920625A (zh)
JP (1)	JPS5035307A (zh)
AU (1)	AU7020674A (zh)
DE (1)	DE2429191A1 (zh)
DK (1)	DK141274B (zh)
ES (1)	ES427365A1 (zh)
FI (1)	FI183974A (zh)
FR (1)	FR2234312B1 (zh)
GB (1)	GB1460607A (zh)
IL (1)	IL44828A0 (zh)
NO (1)	NO742216L (zh)
SE (1)	SE7407445L (zh)
ZA (1)	ZA743896B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2459291C3 (de) *	1974-12-14	1981-06-04	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Verfahren zur Herstellung eines antihämophiles Globulin A enthaltenden Konzentrats neben einem Prothrombin- Komplex und einer Lösung von lagerstabilen Serumproteinen
US4170590A (en) *	1974-12-14	1979-10-09	Biotest-Serum-Institut Gmbh	Ion exchanger treatment of citrate-stabilized plasma
NZ187246A (en) *	1976-03-04	1980-05-27	New Zealand Dev Finance	Hydrophilic hydroxy c2-c4 alkylated crosslinked regenerated cellulose
NZ180199A (en) *	1976-03-04	1978-11-13	New Zealand Dev Finance	Method of testing for the presence of elevated plasma liprotein concentration
JPS52125609A (en) *	1976-04-09	1977-10-21	Green Cross Corp:The	Purification of agglutination factor viii
JPS589824Y2 (ja) *	1977-07-15	1983-02-22	本田技研工業株式会社	車体フレ−ム装置
US4081432A (en) *	1977-07-25	1978-03-28	Monsanto Company	Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers
US4129648A (en) *	1977-11-21	1978-12-12	Collier Harry O J	Method for reducing endogenous prostaglandin synthesis
SE443293B (sv) *	1978-01-25	1986-02-24	Blombaeck E G B	Blodfraktionsframstellning
DE2902158A1 (de) *	1979-01-20	1980-07-31	Biotest Serum Institut Gmbh	Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
US4278594A (en) *	1979-06-19	1981-07-14	David Amrani	Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor (VWF:RCF) and fibronectin from blood plasma
US4210580A (en) *	1979-06-19	1980-07-01	David Amrani	Process for separation and isolation of AHF and fibronectin from blood plasma
SE422081B (sv) *	1979-08-22	1982-02-15	Ird Biomaterial Ab	Sett att pavisa proteolytiska enzymer
SE448945B (sv) *	1979-12-20	1987-03-30	Blombaeck E G B	Forfarande for rening och /eller koncentrering av faktor viii-komplexet
WO1982004395A1 (en) *	1981-06-18	1982-12-23	Erik Gustaf Birger Blombaeck	A process in purification and concentration of the factor viii complex
US4447416A (en) *	1982-04-28	1984-05-08	American National Red Cross	Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US5055557A (en) *	1983-03-04	1991-10-08	Scripps Clinic & Research Foundation	Ultrapurification of factor IX and other vitamin K-dependent proteins
US5614500A (en) *	1983-03-04	1997-03-25	The Scripps Research Institute	Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
US4515714A (en) *	1983-03-09	1985-05-07	Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute	Method for purification of hepatitis B virus surface antigen
US4627915A (en) *	1983-04-06	1986-12-09	Asahi Kasei Kogyo Kabushiki Kaisha	Absorbent of autoantibody and immune complexes, adsorbing device and blood purifying apparatus comprising the same
AT379310B (de) *	1983-05-20	1985-12-27	Immuno Ag	Verfahren zur herstellung eines antithrombin iii-heparin- bzw. antithrombin iii-heparinoidkonzentrates
GB8403473D0 (en) *	1984-02-09	1984-03-14	Special Trustees For St Thomas	Purification of factor viii
US4563303A (en) *	1984-04-14	1986-01-07	Judicial Foundation The Chemosero-Therapeutic Research Institute	Method for purification of filamentous hemagglutinin
US5149787A (en) *	1984-05-22	1992-09-22	The Blood Center Research Foundation	Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
DE3422407A1 (de) *	1984-06-16	1986-03-06	B. Braun Melsungen Ag, 3508 Melsungen	Verwendung von heparinderivaten zur selektiven extrakorporalen praezipitation von low-density-lipoproteinen aus vollserum oder plasma
JPS6147186A (ja) *	1984-08-09	1986-03-07	Chemo Sero Therapeut Res Inst	インフルエンザウイルスの精製方法
JPS6147185A (ja) *	1984-08-09	1986-03-07	Chemo Sero Therapeut Res Inst	日本脳炎ウイルスの精製方法
JPS6147187A (ja) *	1984-08-10	1986-03-07	Chemo Sero Therapeut Res Inst	狂犬病ウイルスの精製方法
JPS6153226A (ja) *	1984-08-24	1986-03-17	Chemo Sero Therapeut Res Inst	単純ヘルペスサブユニツトワクチンの精製方法
US5171569A (en) *	1985-03-15	1992-12-15	National Research Development Corporation	Factor IX preparations uncontaminated by plasma components or pox virus
US4675385A (en) *	1985-03-27	1987-06-23	Alpha Therapeutic Corporation	Isolation of human plasma procoagulant protein factor VIII from biological factors
DE3512910A1 (de) *	1985-04-11	1986-10-16	Behringwerke Ag, 3550 Marburg	Verfahren zur reinigung von plasminogenaktivatoren
US4721572A (en) *	1985-07-12	1988-01-26	Miles Laboratories, Inc.	Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
FR2639958B1 (fr) *	1988-12-06	1992-08-21	Lille Transfusion Sanguine	Support biologique pour cultures cellulaires constitue de proteines plasmatiques coagulees par la thrombine, son utilisation pour la culture des keratinocytes, leur recuperation et leur transport a des fins d'utilisation therapeutique
DE3914869C1 (zh) *	1989-05-05	1990-08-09	Biotest Pharma Gmbh, 6072 Dreieich, De
US4977246A (en) *	1989-06-06	1990-12-11	Rorer Pharmaceutical Corporation	High recovery process for antihemophilic factor
US5110907A (en) *	1989-08-01	1992-05-05	Alpha Therapeutic Corporation	Factor viii complex purification using heparin affinity chromatography
WO1991013976A1 (en) *	1990-03-14	1991-09-19	Yamanouchi Pharmaceutical Co., Ltd.	Process for producing purified tissue plasminogen activator or its derivative
WO1991016063A1 (en) *	1990-04-26	1991-10-31	Uab Research Foundation	System for cryoprecipitating fibrinogen
AT399818B (de) *	1992-04-24	1995-07-25	Immuno Ag	Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
US5520885A (en) *	1993-01-19	1996-05-28	Thermogenesis Corporation	Fibrinogen processing apparatus, method and container
US6770277B1 (en)	1993-06-23	2004-08-03	Beckman Coulter, Inc.	Recombinant DNase B derived from streptococcus pyogenes
DE69433107T2 (de) *	1993-06-23	2004-07-08	Beckman Coulter, Inc., Fullerton	Rekombinante dnase b aus streptococcus pyogenes
US5659017A (en) *	1995-11-07	1997-08-19	Alpha Therapeutic Corporation	Anion exchange process for the purification of Factor VIII
CA2350628A1 (en) *	1998-11-12	2000-05-18	Polymer Biosciences, Inc.	Hemostatic polymer useful for rapid blood coagulation and hemostasis
DE10325304B3 (de) *	2003-06-04	2005-03-24	Fresenius Hemocare Adsorber Technology Gmbh	Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin in Blut oder Blutplasma, Verfahren zu seiner Herstellung und seine Verwendung
FR2952639B1 (fr) *	2009-11-16	2013-08-30	Lab Francais Du Fractionnement	Procede de purification de facteur b
CN107540743A (zh) *	2017-10-11	2018-01-05	南岳生物制药有限公司	一种双层析法制备人纤维蛋白原的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2543808A (en) *	1946-12-26	1951-03-06	Parke Davis & Co	Method of preparing fibrinogen
US3652530A (en) *	1967-08-28	1972-03-28	American Nat Red Cross	Antihemophilic factor prepared from blood plasma using polyethylene glycol
US3631018A (en) *	1970-05-01	1971-12-28	Baxter Laboratories Inc	Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US3682881A (en) *	1970-10-02	1972-08-08	Baxter Laboratories Inc	Fractionation of plasma using glycine and polyethylene glycol
SE392038B (sv) *	1971-09-08	1977-03-14	Kabi Ab	Forfarande for isolering av antitrombin ur blod eller blodprodukter
US3803115A (en) *	1972-05-17	1974-04-09	Baxter Laboratories Inc	Stabilization of ahf using heparin

1973
- 1973-06-19 US US371491A patent/US3920625A/en not_active Expired - Lifetime
1974
- 1974-05-14 IL IL44828A patent/IL44828A0/xx unknown
- 1974-06-06 SE SE7407445A patent/SE7407445L/xx not_active Application Discontinuation
- 1974-06-12 JP JP49066975A patent/JPS5035307A/ja active Pending
- 1974-06-17 FI FI1839/74A patent/FI183974A/fi unknown
- 1974-06-18 GB GB2699774A patent/GB1460607A/en not_active Expired
- 1974-06-18 AU AU70206/74A patent/AU7020674A/en not_active Expired
- 1974-06-18 DK DK324374AA patent/DK141274B/da unknown
- 1974-06-18 ES ES427365A patent/ES427365A1/es not_active Expired
- 1974-06-18 DE DE2429191A patent/DE2429191A1/de active Pending
- 1974-06-18 ZA ZA00743896A patent/ZA743896B/xx unknown
- 1974-06-18 NO NO742216A patent/NO742216L/no unknown
- 1974-06-19 FR FR7421281A patent/FR2234312B1/fr not_active Expired

Also Published As

Publication number	Publication date
ES427365A1 (es)	1976-07-16
FR2234312B1 (zh)	1977-06-24
FI183974A (zh)	1974-12-20
GB1460607A (en)	1977-01-06
JPS5035307A (zh)	1975-04-04
DK141274C (zh)	1980-08-04
DE2429191A1 (de)	1975-01-16
DK141274B (da)	1980-02-18
SE7407445L (zh)	1974-12-20
AU7020674A (en)	1975-12-18
IL44828A0 (en)	1974-07-31
DK324374A (zh)	1975-02-10
ZA743896B (en)	1975-06-25
US3920625A (en)	1975-11-18
FR2234312A1 (zh)	1975-01-17

Publication	Publication Date	Title
NO742216L (zh)	1975-01-13
US4022758A (en)	1977-05-10	Isolation of coagulation factors I and VIII from biological material
US3842061A (en)	1974-10-15	Method for isolation of antithrombin from animal tissue materials by adsorption on sulfated carbohydrate gel
EP0503991B1 (fr)	1998-09-23	Procédé de préparation à l'échelle industrielle d'un concentré de facteur von Willebrand humain standardisé, de très haute pureté, approprié à un usage thérapeutique
Hook et al.	1976	Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin
CA1126652A (en)	1982-06-29	Antithrombin preparation and process for the production thereof
EP0317376B1 (fr)	1993-01-13	Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
AU648655B2 (en)	1994-04-28	Adsorbed cellular fibronectin and process for separating and purifying fibronectins
US5880265A (en)	1999-03-09	Method for isolation of highly pure von willebrand factor
RU1837880C (ru)	1993-08-30	Способ разделени белков крови
WO1981001004A1 (fr)	1981-04-16	Fractions oligosaccharidiques et oligosaccharides possedant des proprietes biologiques, leurs procedes de preparation et leurs applications en tant que medicaments
EP0035202A2 (en)	1981-09-09	Method of blood plasma fractionation
CA2024667C (en)	2001-07-31	Process for preparing a concentrate of blood coagulation factor viii-von willebrand factor complex from total plasma
NO321139B1 (no)	2006-03-27	Farmasoytisk preparat egnet for subkutan, intramuskulaer eller intradermal administrering.
JPH0323528B2 (zh)	1991-03-29
JPS59137417A (ja)	1984-08-07	人尿由来コロニ−形成刺激因子及びカリクレインの製造法
NO138145B (no)	1978-04-03	Fremgangsmaate for fremstilling av et enzympreparat
EP0137356B1 (en)	1989-06-21	Covalently bound heparin - antithrombin-iii complex, method for its preparation and its use for treating thromboembolism
JP2003518513A (ja)	2003-06-10	血漿プロテアーゼからのフィブリノゲンの分離
US3879369A (en)	1975-04-22	Anti-coagulant isolation from malayan pit viper using affinity chromatography
CN109207461B (zh)	2021-09-28	一种凝血因子x激活剂及其制备方法
US3657416A (en)	1972-04-18	Thrombin-like defibrinating enzyme from the venom ancistrodon rhodostoma
JPH0153650B2 (zh)	1989-11-15
US4770877A (en)	1988-09-13	Isolation of a high molecular weight aortic endothelial cell growth inhibitor
NO322527B1 (no)	2006-10-16	Fremgangsmate for rensing av rekombinant Desmodus rotundus-spyttplasminogenaktivator (rDSPA α 1) fra et biologisk medium.